Literature DB >> 22845646

Dietary practices in glutaric aciduria type 1 over 16 years.

H Gokmen-Ozel1, A MacDonald, A Daly, C Ashmore, M A Preece, C Hendriksz, S Vijay, A Chakrapani.   

Abstract

BACKGROUND: In glutaric aciduria type 1 (GA1), dietary treatment with emergency management (EM) is essential to prevent encephalopathic crisis (EC). In the present study, dietary practices were examined in a single UK centre without access to newborn screening.
METHODS: Twenty GA1 patients (11 males, median age: 10.2 years, range 2.2-24.1 years) were evaluated. Nine presented without EC (median diagnosis age: 1.1 years, range 4 days to 8 years) and 11 with EC (median diagnosis age 10 months, range 6 months to 1.7 years). Dietary treatment, neurological outcome, anthropometry and biochemical/haematological markers were assessed.
RESULTS: Diet treatment varied according to age of diagnosis and symptom severity. Four of six pre-encephalopathic children diagnosed before 2 years of age were treated with carnitine, protein restriction (medium l.2 g kg day(-1)) and lysine-free/low tryptophan protein substitute (PS) (medium dose: 1.6 g kg day(-1)). EM consisted of natural protein cessation and glucose polymer with PS delivered via an enteral feeding tube. Older children (>3 years) without EC were given carnitine and protein restriction, and seven of nine EC patients had PS via an enteral feeding tube. Clinical deterioration occurred in two patients without EC; one taking PS and protein restriction (with a second untreatable pathology) and one after protein restriction only. In patients presenting with EC, four died and one had some improvement in movement, with the rest remaining stable but with severe disability. Patients taking PS had better nutritional markers [serum vitamin B(12) (P < 0.001), albumin (P < 0.001), haemoglobin (P < 0.001) and essential plasma amino acids].
CONCLUSIONS: Early diagnosis of GA1 before EC is essential because PS and protein restriction with meticulous EM prevents EC. PS also improves nutritional status irrespective of clinical condition.
© 2012 The Authors. Journal of Human Nutrition and Dietetics © 2012 The British Dietetic Association Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22845646     DOI: 10.1111/j.1365-277X.2012.01269.x

Source DB:  PubMed          Journal:  J Hum Nutr Diet        ISSN: 0952-3871            Impact factor:   3.089


  5 in total

Review 1.  Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision.

Authors:  Nikolas Boy; Chris Mühlhausen; Esther M Maier; Jana Heringer; Birgit Assmann; Peter Burgard; Marjorie Dixon; Sandra Fleissner; Cheryl R Greenberg; Inga Harting; Georg F Hoffmann; Daniela Karall; David M Koeller; Michael B Krawinkel; Jürgen G Okun; Thomas Opladen; Roland Posset; Katja Sahm; Johannes Zschocke; Stefan Kölker
Journal:  J Inherit Metab Dis       Date:  2016-11-16       Impact factor: 4.982

2.  Glutaric Aciduria Type 1: A Case Report and Review of Literature.

Authors:  Sidaraddi Sanju; Milind S Tullu; Nithya Seshadri; Mukesh Agrawal
Journal:  J Pediatr Intensive Care       Date:  2020-04-17

3.  Effects of targeted suppression of glutaryl-CoA dehydrogenase by lentivirus-mediated shRNA and excessive intake of lysine on apoptosis in rat striatal neurons.

Authors:  Jinzhi Gao; Cai Zhang; Xi Fu; Qin Yi; Fengyan Tian; Qin Ning; Xiaoping Luo
Journal:  PLoS One       Date:  2013-05-02       Impact factor: 3.240

4.  Amino Acid Plasma Profiles from a Prolonged-Release Protein Substitute for Phenylketonuria: A Randomized, Single-Dose, Four-Way Crossover Trial in Healthy Volunteers.

Authors:  Mika Scheinin; Anna Barassi; Jouni Junnila; Zsófia Lovró; Giorgio Reiner; Essi Sarkkinen; Anita MacDonald
Journal:  Nutrients       Date:  2020-06-02       Impact factor: 5.717

5.  Inconsistencies in the Nutrition Management of Glutaric Aciduria Type 1: An International Survey.

Authors:  Laurie Bernstein; Curtis R Coughlin; Morgan Drumm; Steven Yannicelli; Fran Rohr
Journal:  Nutrients       Date:  2020-10-16       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.